The Hyderabad-based pharmaceutical company, Lee Pharma, has recently released a statement which says that Saxagliptin hydrochloride is the most effective substitute for insulin injectables for the treatment of Type-2 diabetes. The statement was made while Lee Pharma said that the multinational company AstraZeneca, which it applied to for the patented diabetes medication Saxagliptin hydrochloride, was[…]
Saxagliptin Hydrochloride- The Most Efficient Substitute for Insulin
Anti-Diabetic, Drug Research & Development API, Gliptin, Patent Expiration 2023 Tags: Saxagliptin Dec 15, 2015
Linagliptin Could be the Answer to Macrovascular Complications Type-2 Diabetics
Anti-Diabetic, Blood Glucose Regulator, Drug Research & Development API, Gliptin Tags: anti-diabeticLinagliptin Dec 01, 2015
A new study reveals that patients diagnosed with Type2-diabetes are at an increased risk of developing macrovascular and microvascular complications. Researchers are currently using a drug called Linagliptin which is an anti-diabetic drug that works by increasing the levels of incretins to help control blood sugar levels, especially after meals. According to reports, the cardiovascular[…]
Trelagliptin Succinate NDA in Japan Captures Global Attention of Pharmaceutical World
Anti-Diabetic, Drug Research & Development API, Gliptin, NDA Tags: Sitagliptin Phosphate Apr 09, 2014
Recently, the Trelagliptin Succinate NDA has captured pharmaceutical headlines as it was accepted by the Japanese Ministry of Health, Labour and Welfare. As a unique once weekly treatment for type 2 diabetes, Trelagliptin Succinate is an effectual dipeptidyl peptidase-IV inhibitor. As one of the few providers in the world of Trelagliptin Succinate, LGM Pharma offers[…]
Alogliptin Shines in Three Recent FDA Approvals
Anti-Diabetic, Blood Product, Drug Research & Development API, Gliptin Tags: JanuviaMetformin Hydrochloridetype 2 Diabetes Feb 06, 2013
Alogliptin is a current newsmaker in the pharmaceutical industry. On January 25, 2013 Takeda announced that Alogliptin, CAS# 850649-62-6, was approved alongside Metformin HCl, CAS# 1115-70-4, in the novel type 2 diabetes medication Kazano. As an efficacious and highly selective DPP-4 inhibitor, Alogliptin, when combined in this single dose tablet with metformin HCI effectively aids[…]
Trelagliptin Succinate – a Potential Once a Week Type 2 Diabetes Drug
Blood Glucose Regulator, Blood Product, Gliptin Tags: Januviasitagliptintype 2 Diabetes Nov 05, 2012
Cases of Diabetes, particularly type 2 Diabetes have skyrocketed worldwide and in the United States. According to the National Diabetes Information Clearinghouse Diabetes affects 25.8 million people of all ages, or roughly 8.3 percent of the U.S. population. The majority of these cases in the United States, upwards of 90 percent, are of the type[…]
Linagliptin and Metformin Hydrochloride Tag Team to Combat Type 2 Diabetes
Anti-Diabetic, Antibiotic, Blood Glucose Regulator, Drug Research & Development API, Gliptin Tags: LinagliptinMetformin Hydrochloridetype 2 Diabetes Aug 17, 2012
As a chronic disease which occurs when the body does not properly produce, or use the hormone insulin, type 2 diabetes has become a worldwide problem. Roughly 25.8 million Americans and an estimated 366 million people worldwide have diabetes, according to the CDC and 2011 data from the IDF. Type 2 diabetes accounts for 90-95[…]
Gliptins Give Researchers a Pleasant Cardiovascular Surprise
Anti-Diabetic, Drug Research & Development API, Gliptin Tags: LinagliptinSaxagliptinSitagliptin Phosphate Oct 12, 2011
DDP-4 inhibitors, commonly known as Gliptins, are a relatively new group of drugs. They are drugs normally used for diabetes control, however, this year it was discovered that they may play a greater heart-protective role in patients with existing cardiovascular comorbidities. According to the report published last month in Medpage Today, researchers found that patients[…]
